Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California University of Colorado, Anschutz Cancer Pavilion (ACP(, Aurora, Colorado Winship Cancer Institute, Emory University, Atlanta, Georgia University of Chicago Medical Center, Chicago, Illinois Horizon Oncology Research, Lafayette, Indiana Karmanos Cancer Institute, Detroit, Michigan Comprehensive Cancer Center of Nevada, Las Vegas, Nevada Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey Columbia University Irving Medical Center, New York, New York Carolina BioOncology Institute, Huntersville, North Carolina University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania Fox Chase Cancer Center, Philadelphia, Pennsylvania Medical University of South Carolina (MUSC), Charleston, South Carolina PRISMA Health, Institute for Translational Oncology, Greenville, South Carolina NEXT Oncology, Austin, Texas NEXT Oncology, Irving, Texas NEXT Oncology, Fairfax, Virginia